Ketamine-Assisted Psychotherapy

Gyfts is in early access. Browse modalities, conditions, and practitioner profiles freely. Booking flow opens at full launch.Join the waitlist

Ketamine-Assisted Psychotherapy — Evidence & Practitioners | Gyfts

Background

Origin & History

Ketamine has been used as an anaesthetic since 1970. Its rapid antidepressant properties were first demonstrated by Berman et al. (2000) at Yale University. Johnson & Johnson developed esketamine (Spravato), which received FDA approval in 2019 for treatment-resistant depression. Simultaneously, off-label use of generic racemic ketamine grew rapidly in US ketamine clinics from the mid-2010s. KAP emerged from clinicians who recognised that ketamine''s therapeutic potential was enhanced when combined with psychotherapy rather than administered as a standalone infusion. The Ketamine Research Foundation, MAPS, and various training programmes developed structured KAP protocols. By the mid-2020s, hundreds of KAP clinics operated in the US, with growing presence in Australia, UK, and other jurisdictions. The practice sits at the intersection of psychiatry, psychedelic-assisted therapy, and psychotherapy, with ongoing debate about optimal protocols and practitioner qualifications.

The practice

How It Works

KAP integrates three phases: preparation (psychotherapy sessions establishing rapport, intention, and psychological readiness), medicine session (sub-anaesthetic ketamine administered via IV, IM, sublingual, or intranasal routes in a controlled clinical setting, typically producing a dissociative, dreamlike state lasting 45–90 minutes while a therapist provides support), and integration (subsequent psychotherapy sessions processing the experiences, insights, and emotional material that arose during the medicine session). Ketamine''s mechanism includes rapid NMDA receptor antagonism, increased AMPA receptor signalling, enhanced BDNF release, and promotion of synaptic plasticity — creating a neurobiological window of enhanced plasticity during which psychotherapeutic work may be particularly effective. The combination of pharmacological and psychotherapeutic elements is proposed to produce more durable outcomes than either alone.

What to Expect in a Session

A KAP course typically involves 4–6 medicine sessions over 2–4 weeks, bracketed by preparation and integration therapy. Preparation (1–2 sessions): the therapist and prescribing physician assess suitability, establish therapeutic goals, and prepare the patient psychologically. Medicine session (2–3 hours): in a controlled clinical setting, the patient receives sub-anaesthetic ketamine (routes vary: IV, IM, sublingual, or intranasal) while lying on a comfortable couch, often with eyeshades and music. A therapist is present throughout. The ketamine produces a dissociative, dreamlike state lasting 45–90 minutes. The therapist provides a calm, supportive presence, occasionally offering gentle verbal guidance. Integration sessions (1–2 per medicine session): psychotherapy to process emergent material, consolidate insights, and translate experiences into lasting change. Vital signs are monitored; patients cannot drive after sessions.

Mechanisms

How It’s Proposed to Work

The biological and psychological processes proposed to underlie how Ketamine-Assisted Psychotherapy is thought to work.

NMDA Receptor Antagonism

Ketamine blocks NMDA glutamate receptors, triggering a cascade of downstream effects including increased AMPA signalling, BDNF release, and rapid synaptic plasticity.

Enhanced Neuroplasticity Window

The neurobiological changes induced by ketamine create a time-limited window of enhanced synaptic plasticity during which psychotherapeutic work may be particularly effective at consolidating new patterns.

Dissociative State Facilitation

Sub-anaesthetic ketamine produces a dissociative, dreamlike state that may facilitate access to unconscious material and reduce defensive barriers to therapeutic processing.

Evidence Assessment

Ketamine for depression has moderate to strong evidence as a pharmacological intervention. Esketamine (Spravato) has FDA approval for treatment-resistant depression based on Phase 3 RCTs. Multiple meta-analyses (Caddy et al., 2015; Kishimoto et al., 2016) demonstrate rapid antidepressant effects of IV ketamine. However, the specific evidence for KAP (ketamine PLUS structured psychotherapy) is more limited — most ketamine trials tested the drug alone without concurrent psychotherapy. Dore et al. (2019) published on KAP for treatment-resistant depression showing promising results. Wilkinson et al. (2021) reviewed the rationale for combining ketamine with psychotherapy. The emerging evidence suggests that psychotherapy may extend the durability of ketamine''s antidepressant effects, which tend to be transient (days to weeks) when ketamine is administered alone.

Evidence varies by condition and individual response. This information is for educational purposes only and does not constitute medical advice.

References

Questions

Frequently Asked Questions

Is KAP legal?

Ketamine is a legal, FDA-approved medication prescribed off-label for depression. Esketamine (Spravato) has specific FDA approval for treatment-resistant depression. KAP is legal when ketamine is prescribed by a licensed physician and administered in an appropriate clinical setting.

How is KAP different from ketamine infusions?

Ketamine infusion clinics typically administer IV ketamine for its pharmacological antidepressant effect without concurrent psychotherapy. KAP adds structured preparation and integration therapy, proposing that the combination produces more durable outcomes.

Is KAP safe?

When administered in a supervised clinical setting with proper medical monitoring, KAP has an established safety profile. Side effects include dissociation, nausea, elevated blood pressure, and dizziness. At-home ketamine prescribing raises additional safety concerns.

How quickly does it work?

Ketamine''s antidepressant effects can begin within hours — much faster than conventional antidepressants (which take 4–6 weeks). However, these effects tend to be transient (days to weeks) without repeated administration or psychotherapy integration.

Does insurance cover KAP?

Esketamine (Spravato) may be covered by some insurance plans for treatment-resistant depression. Generic ketamine used off-label and the psychotherapy component are typically not covered. Costs vary significantly by clinic and protocol.

What does the ketamine experience feel like?

At sub-anaesthetic doses, ketamine typically produces a dreamlike, dissociative state. Patients often describe floating sensations, vivid imagery, emotional insights, and altered perception of time and space. The experience is generally gentler than full anaesthesia.

Ask Vidi about Ketamine-Assisted Psychotherapy

Origin & History

How It Works

What to Expect in a Session

How It’s Proposed to Work

NMDA Receptor Antagonism

Enhanced Neuroplasticity Window

Dissociative State Facilitation

References

Frequently Asked Questions

Who Is This For?

Best for

Not ideal for

Commonly used for

Substance Abuse

Depression & Low Mood

Chronic pain

PTSD & Trauma

Anxiety

Symptoms practitioners commonly work with